BRENNEN

Industries / Health / Medical devices

Testing and approval

Before a device can be sold, its maker must show a regulator, or a firm the regulator appoints, that it is safe and does what it claims, using bench tests, lab and animal studies and sometimes studies in people.

7

Milestones achieved, from 1976 to 2025.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 1976

    Devices brought under review

    The Medical Device Amendments, signed on 28 May 1976, gave the FDA power to review devices before sale and sorted them into three classes by risk. Most high-risk devices now needed premarket approval (PMA), with evidence of safety and effectiveness; others could use premarket notification, called the 510(k) after its section of the law, which asks whether a device matches one already on the market. The push came from the Dalkon Shield, an intrauterine contraceptive sold from 1971 with no federal review, which about 2.2 million US women had received by 1974 before its maker recalled it.

    LessonUS device review began after harm, not before it.

    govinfo.govjoe-prod.ama-assn.orgfda.gov

    Credit

    US Congress (Public Law 94-295), building on the Cooper Committee of 1970, chaired by Theodore Cooper, which proposed classing devices by risk

  2. 1977

    One safety standard for machines

    The International Electrotechnical Commission (IEC) published IEC 60601-1, "Medical electrical equipment. Part 1: General requirements", in January 1977. It gave makers of powered medical equipment one shared set of safety requirements to design and test against. Later editions changed the title to "General requirements for basic safety and essential performance", adding the clinical functions a device must keep performing to stay safe.

    online.standard.no

    Credit

    IEC

  3. 1993

    Europe's CE mark for devices

    Council Directive 93/42/EEC of 14 June 1993 replaced differing national rules with one set, which member states applied from 1 January 1995. It sorted devices into Classes I, IIa, IIb and III. For the higher classes, the maker's evidence is checked by a notified body, a private firm that a government designates, before the device carries the CE marking, and no member state may then block its sale.

    eur-lex.europa.eu

    Credit

    Council of the European Communities

  4. 2011

    Review urges replacing the 510(k)

    A committee of the Institute of Medicine (IOM), a US national academy, reviewed the 510(k) at 35 years. It concluded that, with limited exceptions, the 510(k) "is not intended to evaluate the safety and effectiveness" of devices, only their likeness to devices already sold, and recommended that the FDA gather the information needed to replace it with one framework covering devices before and after sale.

    Lessona critical review did not retire the route; in 2017, 3,173 devices, 82% of all those cleared or approved that year, reached the market through the 510(k), by the count in a 2021 AMA Journal of Ethics review.

    nationalacademies.orgjoe-prod.ama-assn.org

    Credit

    Institute of Medicine

  5. 2017

    One audit, five regulators

    Under the Medical Device Single Audit Program (MDSAP), one recognized auditing firm inspects a maker's quality system once, and the regulators of Australia, Brazil, Canada, Japan and the US accept the result. Work on it began at the first meeting of the International Medical Device Regulators Forum (IMDRF) in Singapore in 2012. After a pilot from 2014 to 2016, a final report in 2017 found the program viable, and the FDA accepts MDSAP audit reports in place of its routine inspections.

    fda.gov

    Credit

    IMDRF and the MDSAP Regulatory Authority Council

  6. 2017

    Europe rewrites its device law

    French health authorities found that the maker Poly Implant Prothèse (PIP) had filled breast implants with industrial silicone instead of the medical-grade silicone named in its approval files. About 400,000 had been sold worldwide, by European Commission figures that the European Parliament cited in June 2012. Regulation (EU) 2017/745, adopted on 5 April 2017 and applied from 26 May 2021 after a one-year delay for COVID-19, gives notified bodies the right and duty to make unannounced visits and test devices, requires an implant card for each patient, and sets up EUDAMED, an EU device database.

    Lessona check of a maker's paperwork missed a fraud on its factory floor.

    eur-lex.europa.eueur-lex.europa.eueur-lex.europa.eu

    Credit

    European Parliament and Council of the EU

  7. 2025

    China's fast lane for devices

    China's regulator, the National Medical Products Administration (NMPA), runs a special review procedure, often called the green channel, that gives devices it judges both original and clinically valuable earlier contact with reviewers. Its 2025 annual registration report, released on 24 February 2026, counts 76 such devices approved in 2025 and 391 by the end of 2025, 55 of them imported, as summarized by the consultancy Cisema.

    cisema.comcisema.com

    Credit

    NMPA and its Center for Medical Device Evaluation (CMDE)

Watch for

  1. Lighter EU device rules

    The European Commission proposed changes to the 2017 device regulations on 16 December 2025. They would lower the risk class of some devices and have notified bodies give priority to breakthrough devices and orphan devices, meaning devices for rare conditions; the Commission estimates savings of about €3.3 billion a year. In November 2026 the proposal was still at committee stage in the European Parliament, with a draft report in June and amendments in July 2026.

    Achieved whenthe Parliament and the Council adopt the regulation and it is published in the Official Journal of the EU.

    oeil.secure.europarl.europa.eumedtechdive.com

    Claimed by

    European Commission, December 2025

  2. UK reliance on foreign approvals

    Britain's regulator plans a shorter route to market for some devices already approved in Australia, Canada or the US, ending in a Certificate of International Reliance instead of a separate UK conformity mark. Draft regulations were published in May 2026; the law firm Hogan Lovells expects them to be adopted in December 2026 and the reliance route to open in mid-2028.

    Achieved whenthe regulations are made and a first device reaches the British market on a Certificate of International Reliance.

    gov.ukhoganlovells.com

    Claimed by

    Medicines and Healthcare products Regulatory Agency (MHRA), July 2025

Open

  1. 01

    Approval dates across regulators

    A public table of every device the FDA approved through premarket approval (PMA), its route for the highest-risk devices, from 2015 to 2025, with the date the same device was approved or certified in the EU, Japan, Canada, Australia and China, and the gap between each pair of regulators in months. Each date links to the regulator's public record.

    The brief
    Credit · unclaimed
  2. 02

    Tests behind every clearance

    A public table that lists, for every 510(k) clearance from 2020 to 2025, each test its public summary names: the consensus standard and its edition (for example IEC 60601-1 for electrical safety) and the kind of test (bench, biocompatibility, electrical safety, software, animal or clinical). Each row quotes the sentence it came from, and summaries that name no test are flagged.

    The brief
    Credit · unclaimed

Open 01 · the brief

Approval dates across regulators

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public table of every device the FDA approved through premarket approval (PMA), its route for the highest-risk devices, from 2015 to 2025, with the date the same device was approved or certified in the EU, Japan, Canada, Australia and China, and the gap between each pair of regulators in months. Each date links to the regulator's public record.

Why it is still open

The most recent study found covers 26 heart ablation catheters only. Gaku Oguri, Katsuhito Fujiu and Norihiko Takeda (2026) found that Japan's approvals came a mean 46.2 months after the EU's and 16.7 months after the US's, and US approvals 29.5 months after the EU's. A wider 2016 study in The BMJ, by Hwang, Sokolov, Franklin and Kesselheim, followed 309 new heart, bone and brain devices CE-marked in the EU from 2005 to 2010 found 206 approved in both regions and 129 of those approved in the EU first, but compared only those two regions and did not publish a refreshed table. No public table across device types and regulators was found, and EU certificates only had to be entered in EUDAMED from 28 May 2026.

pmc.ncbi.nlm.nih.govapi.openalex.orghealth.ec.europa.eu

Built with what exists

the openFDA premarket approval endpoint (57,518 records, including later changes to approved devices); Health Canada's Medical Devices Active Licence Listing; the Australian Register of Therapeutic Goods; EUDAMED's public certificate search; PMDA and NMPA approval lists; a language model such as Claude or Gemini to match device names across languages, with a person checking each match. Yes-or-no matching at scale is the kind of job in the Note "A thousand questions, one pass".

  1. First step

    Take the original PMA approvals of 2024 from openFDA (records with no supplement number) and look up each maker and device by hand in the Canadian and Australian registers.

  2. Done looks like

    At least 300 PMA devices matched in at least four of the six regulators, each date linked to its public record. A second person rechecks 50 random rows and agrees with at least 95%. Median gaps for each pair of regulators are published, and the table is refreshed every quarter for a year.

Open 02 · the brief

Tests behind every clearance

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public table that lists, for every 510(k) clearance from 2020 to 2025, each test its public summary names: the consensus standard and its edition (for example IEC 60601-1 for electrical safety) and the kind of test (bench, biocompatibility, electrical safety, software, animal or clinical). Each row quotes the sentence it came from, and summaries that name no test are flagged.

Why it is still open

510(k) summaries are free-text PDFs with no structured field for tests. Bradley Merrill Thompson of the law firm Epstein Becker Green ran language processing over tens of thousands of summaries in 2023, found performance figures in about 570 from 2001 to May 2023, and called the result imprecise. The regulatory software firm Complizen screened the 3,070 summaries for 2025 clearances for clinical data only and found it in at least 17%. Neither published a table per clearance, and neither counted standards. Closest is Innolitics' free FDA browser, which shows for each clearance text OCR'd from FDA records, including the standards and tests named, and exports search results to Excel; it publishes no accuracy check, and its page for one 2020 surgical robot clearance (K193534) says "bench testing only" while also describing animal and cadaver studies.

ebglaw.comcomplizen.aifda.innolitics.com

Built with what exists

the openFDA 510(k) endpoint (176,683 records) for the list of clearances; the summary PDFs on FDA's site; pdftotext, with Tesseract OCR for scanned summaries; a language model such as Claude or Gemini to pull out each test with its quoted sentence (see the Note "The jobs agents repeat"); the FDA's Recognized Consensus Standards database to check standard numbers; DuckDB to hold the table.

  1. First step

    Download the 2025 summaries for one product code with many clearances, label 50 by hand, and compare a model's output with your labels.

  2. Done looks like

    All clearances from 2020 to 2025 processed. A second person checks 300 random summaries and agrees with at least 95% of the standards and test types extracted. The table, the code and the checked sample are public.